Welcome to our dedicated page for Cytodyn SEC filings (Ticker: CYDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytoDyn Inc. filings document a clinical-stage oncology company advancing leronlimab, its CCR5-targeted monoclonal antibody. The filing record includes Regulation FD materials for corporate and clinical updates, registration statements tied to common stock and warrant securities, and risk disclosures related to clinical development, regulatory approval, financing needs, and commercialization.
Material-event reports cover private placements of common stock and warrants, standby equity purchase arrangements, secured convertible promissory note amendments, and other capital-structure matters. Proxy and annual-meeting filings document director elections, auditor votes, authorized-share amendments, executive compensation, equity awards, and other governance matters for the Delaware issuer.
CytoDyn Inc. reported that Chief Executive Officer Jacob P. Lalezari received a grant of non-qualified stock options for 4,874,691.0000 shares of common stock at an exercise price of $0.2800 per share as his annual fiscal 2026 award under the 2012 Equity Incentive Plan.
According to the vesting schedule, 1,218,672 underlying shares will vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, subject to continuous service. This is a compensation-related, non-market transaction.
CytoDyn Inc. reported that Chief Financial Officer Robert E. Hoffman received a grant of non-qualified stock options covering 4,874,691 shares of common stock. The options have an exercise price of $0.28 per share and expire on March 20, 2036.
This award represents his annual equity grant for fiscal year 2026 under CytoDyn's 2012 Equity Incentive Plan. Vesting is time-based: 1,218,672 shares vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, contingent on continued service.
CytoDyn Inc. director Dunlap Ryan reported receiving a grant of non-qualified stock options to buy 574,385 shares of common stock. The options have an exercise price of $0.28 per share and expire in March 2036. This award represents his annual fiscal 2026 grant under CytoDyn's 2012 Equity Incentive Plan.
The options vest in 12 approximately equal monthly installments from April 2026 through March 2027, conditioned on continued service. After this grant, Ryan holds 574,385 derivative securities, and the filing does not show any open-market purchases or sales of CytoDyn common stock.
CytoDyn Inc. director Karen J. Brunke received a grant of non-qualified stock options covering 574,385 shares of common stock. The options have an exercise price of $0.28 per share and were approved as her annual fiscal 2026 grant under CytoDyn's 2012 Equity Incentive Plan.
The award vests in 12 approximately equal monthly installments from April 2026 through March 2027, subject to continuous service. Following this grant, Brunke holds 574,385 derivative securities in the form of these options directly.
CytoDyn Inc. reported that Chief Legal Officer Tyler Blok received a grant of non-qualified stock options as part of his fiscal 2026 compensation. The award covers 3,249,794 options to buy common stock at an exercise price of $0.28 per share, expiring in 2036.
The grant was approved by the Compensation Committee on March 20, 2026 under CytoDyn’s 2012 Equity Incentive Plan. 812,448 underlying shares will vest on March 20, 2027, with the remaining options vesting in roughly equal monthly installments from April 2027 through March 2030, subject to continuous service.
CytoDyn Inc. amended two secured convertible promissory notes originally issued in April 2021, each with an initial principal amount of $28.5 million. On March 24, 2026, the company and the noteholders agreed to extend the maturity dates of these notes by 36 months to April 5, 2029 and April 23, 2029, respectively.
As consideration for the extensions, CytoDyn will make combined monthly payments valued at $1,000,000 in shares of common stock through the new maturity dates, with the share value based on the lower of the prior day’s closing price or the average closing price over the previous five trading days. The annual interest rate on each note was reduced to 5%, lowering the cash interest burden while committing to ongoing equity-based payments.
CytoDyn files a prospectus supplement registering up to 375,999,668 shares of common stock for resale, consisting of 181,324,099 shares being resold and 194,675,569 shares issuable upon exercise of warrants. The supplement updates the Form S-1 prospectus and incorporates the Company’s Form 8-K disclosure dated February 27, 2026.
The 8-K discloses private financings completed in January–February 2026: a placement-agent-led private unit offering of approximately 81.4 million units for approximately $17.5 million, direct private sales including 3,944,773 shares for about $1.0 million, a SEPA issuance of ~0.8 million shares for ~$0.2 million, and convertible-note exchanges issuing ~5.9 million shares.
CytoDyn Inc. reported several recent private financing transactions that together raised new cash and issued additional common shares and warrants. Through a placement agent offering begun in January 2026, the company received binding subscriptions for about 81.4 million units at $0.2153 per unit, for roughly $17.5 million in cash; each unit includes one share and a five-year warrant with a $0.26 exercise price. CytoDyn also sold 3,944,773 shares directly to an accredited investor for about $1.0 million, and a separate investor bought 464,468 similar units for $100,000. Under a standby equity purchase agreement with Yorkville, the company issued about 0.8 million shares for roughly $0.2 million. In addition, it exchanged portions of a convertible note into new notes and issued about 5.9 million shares to the noteholder in satisfaction of $1.5 million of principal.
CytoDyn Inc. files a prospectus supplement covering the resale of up to 375,999,668 shares of common stock, including 181,324,099 outstanding shares and 194,675,569 shares issuable upon warrant exercise, by existing stockholders.
The supplement incorporates CytoDyn’s latest quarterly report for the period ended November 30, 2025, which shows cash and cash equivalents of $4.98 million, current liabilities of $85.11 million, total liabilities of $128.68 million, and a stockholders’ deficit of $119.75 million. The company reported a net loss of $22.61 million for the quarter and $28.15 million for the six-month period, and discloses that these conditions raise substantial doubt about its ability to continue as a going concern. CytoDyn outlines a standby equity purchase agreement of up to $30 million, significant outstanding convertible notes, and an agreement in principle to settle a securities class action with $500,000 in cash and 49 million shares.
CytoDyn Inc. reported a much larger net loss for the quarter ended November 30, 2025 as it booked a sizable legal settlement accrual and continued funding development of its antibody leronlimab for cancer. Quarterly net loss was $22.6M versus $4.8M a year earlier, driven mainly by a $16.6M legal settlement loss. For the first six months, the company lost $28.1M compared with prior-year profit that was boosted by a one-time clinical expense return.
Cash and cash equivalents fell to $5.0M while current liabilities reached $85.1M, including convertible notes and accrued interest. Management states that recurring losses, an accumulated deficit of about $915.9M, and looming obligations raise substantial doubt about CytoDyn’s ability to continue as a going concern without new financing. To access capital, the company put in place a standby equity purchase agreement allowing sales of up to $30M of stock and shareholders approved an increase in authorized common shares to 2.25 billion.